Arovella Therapeutics ASX: ALA

The iNKT Cell Therapy Revolution In this video, we are going to explain what cell therapy is, and in particular, invariant natural killer T (i-N-K-T) cell therapy — in combination with CARs (chimeric antigen receptors). After watching this video, you will be able to explain the ‘cell therapy revolution’ and grasp its future potential in the fight against cancer. Welcome to Arovella Therapeutics ASX: ALA - at the time of making this video, we are the only Australian biotech company developing an iNKT cell therapy platform. Our core focus is on developing therapies to treat cancers. #iNKT #CellTherapy #Arovella

Friday's webinar will discuss battery minerals, radiopharmaceutical products and cancer treatments. Register now https://bit.ly/4cXvNKO to hear from QX Resources ASX: QXR, Radiopharm Theranostics ASX: RAD & Arovella Therapeutics ASX: ALA

Investor Presentation: Non-Deal Roadshows this week in Australia View below or via https://lnkd.in/gwWzEy4r #Investors #iNKT #CellTherapy #InvestorPresentation #ASX #MedTech

We are pleased with the research desk note prepared by Spark Plus describing our current product pipeline and ambitions to tackle a range of blood cancers and solid tumours. Read the Spark Plus desk note: https://lnkd.in/gy7aRJvT View our product pipeline: https://lnkd.in/g3TZjHre #iNKT #CellTherapy #Biotech #Biotechnology #ASX #EndCancer #MedTech

A new desk note from Spark Plus analyst Cyprus Sia has provided a comprehensive look at Arovella Therapeutics ASX: ALA and the work the biotech company is doing towards developing invariant natural killer T (iNKT) cell therapies, including its pioneering ‘armoured’ CAR-iNKT product. More at #Proactive #ProactiveInvestors #ALA http://ow.ly/yZcG105wrYA

We agree that the biotech sector continues to be one to watch, and that Arovella has compelling early-stage data. We are looking forward to advancing ALA-101 into first-in-human trials! #iNKTcells #cancerpatients #biotechnology #cancerresearch #celltherapy https://lnkd.in/gwpCt9vb

Biotech company Arovella Therapeutics ASX: ALA, which specialises in invariant Natural Killer T (iNKT) cell therapy, has hit a milestone in the process development for its lead product, ALA-101. The company has finalised the critical process for Good Manufacturing Practice (GMP) manufacturing of ALA-101, which demonstrates a high yield of Chimeric Antigen Receptor (CAR) 19-positive iNKT cells with exceptional purity. Arovella’s proprietary manufacturing process represents a leap forward in the development of iNKT cell therapy. The modular, semi-automated process, developed at Cell Therapies Pty Ltd, is suitable for large-scale manufacturing and late-phase clinical development. This process is crucial for regulatory approval for first-in-human clinical trials, allowing Arovella to progress to engineering and GMP batches to produce material for phase 1 clinical trials. More at #Proactive #ProactiveInvestors #Biotech #iNKT #Oncology #Medtech http://ow.ly/W2SK105vAsa

It’s great to be at BIO in San Diego having many interesting discussions! Good timing as Arovella Therapeutics ASX: ALA just ticked off a key milestone for ALA-101, completing process development and manufacturing scale-up. Fantastic effort from an outstanding team and from Cell Therapies Pty Ltd! #bio2024 #celltherapy #cancerresearch #cancerpatients

We have just announced on the ASX a significant milestone that we have completed the process development for our patent protected manufacturing process required for large-scale Good Manufacturing Practice (GMP) of ALA-101, our lead product (https://lnkd.in/geV_y4vp). Dr Michael Baker, CEO & MD has commented: “Process development for our CAR-iNKT manufacturing process has been a primary focus for Arovella over the past year, and it is incredibly exciting to have completed this step. For all cell therapy products, the manufacturing process defines your product. We have been diligent to ensure that our proprietary manufacturing process is robust and delivers high-yield, high- purity products. This enables us to achieve our vision of taking allogeneic CAR-iNKT cells into clinical trials and, ultimately, commercial development. I am proud of the team for achieving this milestone and thankful to Cell Therapies Pty Ltd for their partnership and the experience they have contributed. We look forward to continuing this momentum as we progress towards our phase 1 clinical trial for ALA-101.” More at: https://lnkd.in/gRTusVc7

Look out for our CEO, Dr Michael Baker who is attending this year's BIO 2024 International Convention to speak with, and learn from some of the industry's top experts and pioneers #BIO2024 #Arovella #iNKT #CellTherapy #ASX